Shandong Sito Bio-technology Co Ltd (300583) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥15.13 Million ≈ $2.21 Million USD) by net assets (CN¥1.80 Billion ≈ $263.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shandong Sito Bio-technology Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300583 current and long-term liabilities for a breakdown of total debt and financial obligations.
Shandong Sito Bio-technology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Sito Bio-technology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qingdao Richen Food Co Ltd
SHG:603755
|
0.033x |
|
PT Temas Tbk
JK:TMAS
|
0.079x |
|
Atrium Mortgage Investment Corp
TO:AI
|
-0.048x |
|
THONBURI HEALTHCARE GRO-NVDR
BK:THG-R
|
N/A |
|
CoAsia Microelectronics
TWO:8096
|
-0.504x |
|
Nexus Real Estate Investment Trust
TO:NXR-UN
|
0.026x |
|
Chongqing YuXin Pingrui Electronic Co. Ltd.
SHE:301107
|
0.011x |
|
DINE S.A.B. de C.V
MX:DINEB
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Shandong Sito Bio-technology Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Sito Bio-technology Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Shandong Sito Bio-technology Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.88 Billion ≈ $275.71 Million |
CN¥194.46 Million ≈ $28.46 Million |
0.103x | +329.60% |
| 2023-12-31 | CN¥2.07 Billion ≈ $302.24 Million |
CN¥-92.85 Million ≈ $-13.59 Million |
-0.045x | -154.77% |
| 2022-12-31 | CN¥1.77 Billion ≈ $259.14 Million |
CN¥145.34 Million ≈ $21.27 Million |
0.082x | -37.48% |
| 2021-12-31 | CN¥1.73 Billion ≈ $253.45 Million |
CN¥227.35 Million ≈ $33.27 Million |
0.131x | -12.80% |
| 2020-12-31 | CN¥1.69 Billion ≈ $247.50 Million |
CN¥254.60 Million ≈ $37.26 Million |
0.151x | +392.93% |
| 2019-12-31 | CN¥1.89 Billion ≈ $276.09 Million |
CN¥57.62 Million ≈ $8.43 Million |
0.031x | +117.00% |
| 2018-12-31 | CN¥1.86 Billion ≈ $272.45 Million |
CN¥-334.41 Million ≈ $-48.94 Million |
-0.180x | -2914.08% |
| 2017-12-31 | CN¥1.71 Billion ≈ $249.81 Million |
CN¥10.90 Million ≈ $1.59 Million |
0.006x | -95.20% |
| 2016-12-31 | CN¥603.01 Million ≈ $88.24 Million |
CN¥80.15 Million ≈ $11.73 Million |
0.133x | -22.69% |
| 2015-12-31 | CN¥506.66 Million ≈ $74.14 Million |
CN¥87.10 Million ≈ $12.75 Million |
0.172x | -71.35% |
| 2014-12-31 | CN¥290.80 Million ≈ $42.55 Million |
CN¥174.49 Million ≈ $25.53 Million |
0.600x | +137.69% |
| 2013-12-31 | CN¥98.83 Million ≈ $14.46 Million |
CN¥24.95 Million ≈ $3.65 Million |
0.252x | +126.87% |
| 2012-12-31 | CN¥32.47 Million ≈ $4.75 Million |
CN¥-30.50 Million ≈ $-4.46 Million |
-0.939x | -- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more